Due to their ability to intrinsic apoptosis signaling, recent reports demonstrate synergistic activity of BET inhibitors and the small-molecule BCL-2 inhibitor ABT199/venetoclax in killing MYC-driven B-cell lymphoma cells [306,309,310]. Here, BCL2 is linked to B-cell non-Hodgkin lymphoma.